373 related articles for article (PubMed ID: 30462830)
1. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.
Nichols R; Doty E; Sacco S; Ruff D; Pearlman E; Aurora SK
Headache; 2019 Feb; 59(2):192-204. PubMed ID: 30462830
[TBL] [Abstract][Full Text] [Related]
2. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
7. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
Tepper SJ; Dong Y; Vincent M; Wietecha LA
Headache; 2023; 63(10):1380-1390. PubMed ID: 37132481
[TBL] [Abstract][Full Text] [Related]
8. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
Schwedt TJ; Kuruppu DK; Dong Y; Standley K; Yunes-Medina L; Pearlman E
J Headache Pain; 2021 Mar; 22(1):15. PubMed ID: 33765912
[TBL] [Abstract][Full Text] [Related]
9. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
[TBL] [Abstract][Full Text] [Related]
10. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
[TBL] [Abstract][Full Text] [Related]
11. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
12. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
Dodick DW; Doty EG; Aurora SK; Ruff DD; Stauffer VL; Jedynak J; Dong Y; Pearlman EM
Cephalalgia; 2021 Mar; 41(3):340-352. PubMed ID: 33143451
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine.
Yang CP; Lee CF; Dell'Agnello G; Hundemer HP; Lipsius S; Wang SJ
Curr Med Res Opin; 2020 Oct; 36(10):1653-1666. PubMed ID: 32845740
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
16. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis.
Pozo-Rosich P; Samaan KH; Schwedt TJ; Nicholson RA; Rettiganti M; Pearlman EM
Adv Ther; 2021 Jun; 38(6):3154-3165. PubMed ID: 33950375
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
18. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.
Goadsby PJ; Dodick DW; Martinez JM; Ferguson MB; Oakes TM; Zhang Q; Skljarevski V; Aurora SK
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):939-944. PubMed ID: 31004075
[TBL] [Abstract][Full Text] [Related]
19. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
[TBL] [Abstract][Full Text] [Related]
20. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
